According to a narrative review published in medical literature, overactive mast cells may drive persistent nerve pain and neurological symptoms in long COVID patients by triggering small-fiber neuropathy. The condition, which frequently escapes detection on standard nerve conduction tests, stems from direct interactions between the SARS-CoV-2 spike protein and immune cell receptors, setting off inflammatory cascades that sensitize peripheral pain pathways.
Mast Cell Activation and Small Fiber Neuropathy in Long COVID
Long COVID—officially classified as post-acute sequelae of SARS-CoV-2 infection—continues to affect millions of patients globally, with prevalence estimates reaching up to 36% in broad meta-analyses. Among the most debilitating manifestations is neuropathic pain, characterized by burning sensations, numbness, and tingling in the extremities. Morcos and Theoharis C. Theoharides, this damage frequently targets small unmyelinated nerve endings in the skin and organs that regulate pain and temperature.
Because standard clinical nerve conduction studies evaluate only large myelinated nerve fibers, small-fiber pathology often remains invisible to traditional diagnostics. The published review highlights that chronic mast cell activation acts as a primary biological driver behind this hidden nerve damage. Positioned closely near blood vessels and nerve endings, mast cells serve as immune sentinels. When persistently stimulated, they undergo degranulation, releasing inflammatory mediators that continually irritate adjacent nerve fibers.
Spike Protein Triggers and Blood-Brain Barrier Disruption
Cellular mechanisms identified in the review indicate that the SARS-CoV-2 spike protein can bind directly to specific receptors on the surface of mast cells, including angiotensin-converting enzyme 2 (ACE2) and Toll-like receptor 4 (TLR4). This binding prompts the release of inflammatory chemicals without requiring a classic allergic trigger. These molecules bathe nearby nerve endings, compromising structural integrity over time and disrupting autonomic nervous system signals that control heart rate and digestion, which can contribute to conditions like Postural Orthostatic Tachycardia Syndrome (POTS).
Beyond peripheral nerves, circulating mast cell mediators can travel through the bloodstream and compromise the blood-brain barrier. According to the study authors, a weakened barrier allows inflammatory molecules and immune cells to infiltrate the central nervous system, activating resident microglia cells. This central neuroinflammation correlates with severe fatigue and cognitive symptoms commonly referred to as brain fog.
Therapeutic Approaches and Study Limitations
While the mechanistic model offers clear biological plausibility, the review emphasizes significant evidentiary boundaries. Narrative reviews synthesize data from cell cultures, animal models, and clinical case reports but cannot replace controlled experimental trials. Furthermore, blood tests measuring systemic mast cell activation do not consistently show elevated markers across all patient cohorts, suggesting that activation may occur locally within specific tissues rather than uniformly throughout the bloodstream.
To address these complex symptom profiles, researchers are evaluating several targeted interventions:
- Antihistamines: Designed to block histamine receptors and mitigate specific allergic pathways, though clinical results remain mixed because mast cells release numerous other inflammatory mediators.
- Flavonoids: Plant compounds such as luteolin and quercetin, which laboratory studies suggest can stabilize mast cells and prevent the expulsion of inflammatory chemicals.
- Alpha-Liponsäure (Alpha-Lipoic Acid): A naturally occurring antioxidant studied for its potential to neutralize oxidative stress, support nerve regeneration, and dampen pain signaling.
Medical experts emphasize that because long COVID functions as an umbrella term encompassing overlapping biological drivers, a single standardized treatment template will not work for every patient. The authors call for prospective clinical trials that track mast cell activity over time to better correlate immune markers with neuropathic and cognitive endpoints.
Related reading